CFGI’s Capital Markets team assisted Vor Biopharma (NASDAQ: VOR) with their initial public offering. The offering priced 11,302,219 shares of common stock, including 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at $18.00 per share for gross proceeds of approximately $203.4 million, before deducting underwriting discounts, commissions and offering expenses. The shares began trading on February 5, 2021, and the offering closed on February 9, 2021.
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, Vor Biopharma designs these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.
The CFGI team was led by April Coleman (Capital Markets) and Ray D’Eon (Capital Markets) with support from John Ngari (Accounting Advisory).
For further information on the offering, please read Vor Biopharma’s press release.